CLINICAL_TRIALS
trial_result
· 2020-12-23
Clinical Trial Update: Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma [Phase 2]
Summary
Phase 2 trial evaluating neoadjuvant immunotherapy in resectable pancreatic ductal adenocarcinoma was terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Gulam Manji | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-12-23